Corporate Background

“The KREX™ technology is a continuously evolving platform. In the near future, I think we will realise my original vision of not only identifying new autoantibody biomarkers for precision immuno-profiling but also protective autoantibodies that may have enormous therapeutic potential.”

Professor Jonathan Blackburn

Sengenics CSO

About Us

Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics.

The key application of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events. Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests.

Sengenics currently has commercial partnerships with 9 out of the top 10 pharma to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2021.

Invited to autoimmune and cancer steering committees:

Industrial Advisory Board Member:

Member:

FEATURED PRODUCTS

High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics UK Ltd. Registered in England and Wales no. 12889389 | Sengenics Corporation Pte. Ltd. Registered in Singapore no. 201734100D